GlycoNex Incorporation

Equities

4168

TW0004168000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
28.2 ^TWD	+9.94%		+13.25%	-5.21%

05-28	Glyconex and Precisemab Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

GlycoNex Inc. acquired property at Sijhih District, New Taipei from Farglory Land Development Co Ltd for approximately TWD 850 million.

November 20, 2014 at 04:00 am

GlycoNex Inc. (GTSM:4168) acquired property at Sijhih District, New Taipei from Farglory Land Development Co Ltd (TSEC:5522) for approximately TWD 850 million on November 19, 2014. Home Ban Appraisers Joint Firm acted as appraiser in the deal. Farglory Realty Co., Ltd acted as broker in the transaction.

GlycoNex Inc. (GTSM:4168) completed the acquisition of property at Sijhih District, New Taipei from Farglory Land Development Co Ltd (TSEC:5522) on November 19, 2014.

Latest news about GlycoNex Incorporation

Glyconex and Precisemab Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy	05-28	CI
GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021	25/03/22	CI
GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/11/21	CI
Glyconex Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Glyconex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
Glyconex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2020	21/03/21	CI
Glyconex Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	12/08/20	CI
Glyconex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2020	13/05/20	CI
Glyconex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2019	29/03/20	CI
Glyconex Incorporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	10/11/19	CI
Glyconex Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	12/08/19	CI
Glyconex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2019	13/05/19	CI
Glyconex Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	21/03/19	CI
GlycoNex Incorporation Reports Earnings Results for the Third Quarter Ended September 30, 2018	11/11/18	CI
GlycoNex Incorporation(GTSM:4168) dropped from S&P Global BMI Index	18/09/17	CI
GlycoNex Inc. announced a financing transaction	06/07/17	CI

Chart GlycoNex Incorporation

Duration

Period

More charts

Company Profile

GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Sector

Biotechnology & Medical Research

Calendar

02/06/2024 - BIO International Convention

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLYCONEX INCORPORATION	-5.21%	94.2M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research